logo

LSTA

Lisata Therapeutics·NASDAQ
--
--(--)
--
--(--)
2.80 / 10
Underperform

Financial analysis yields a weak rating (2.8/10). Key positives include Profit-MV and Cash-MV, but risks arise from Net profit / Total profit (%) and Revenue-MV. Overall, the fundamental picture is constrained, suggesting limited long-term upside without material improvement in profitability or revenue growth.

Fundamental(2.8)SentimentTechnical

Analysis Checks(6/10)

Revenue-MV
Value-0.26
Score1/3
Weight10.15%
1M Return5.20%
Inventory turnover ratio
Value47.85
Score3/3
Weight8.92%
1M Return5.26%
Gross profit margin (%)
Value100.00
Score1/3
Weight-0.78%
1M Return-0.54%
Profit-MV
Value0.46
Score2/3
Weight15.19%
1M Return7.79%
PB-ROE
Value-0.01
Score1/3
Weight14.03%
1M Return7.02%
Current assets turnover ratio
Value0.00
Score2/3
Weight1.78%
1M Return1.15%
Fixed assets turnover ratio
Value1.49
Score3/3
Weight1.30%
1M Return0.86%
Asset-MV
Value-0.50
Score2/3
Weight34.66%
1M Return15.13%
Cash-MV
Value-0.07
Score2/3
Weight15.21%
1M Return7.73%
Net profit / Total profit (%)
Value93.41
Score0/3
Weight-0.45%
1M Return-0.30%
Is LSTA fundamentally strong?
  • LSTA scores 2.80/10 on fundamentals and holds a Premium valuation at present. Backed by its -58.71% ROE, -1704.86% net margin, -2.20 P/E ratio, 2.34 P/B ratio, and 15.14% earnings growth, these metrics solidify its Underperform investment rating.